# A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension

Study · id `cardio:ct-nct06671392` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06671392](<https://clinicaltrials.gov/study/NCT06671392>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06671392

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 198 participants.

## Technical summary

Registry record NCT06671392. Randomized; double masking; primary purpose treatment. Start 2025-02-24 (actual); primary completion 2026-02-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 198 participants (enrolled count; ClinicalTrials.gov record NCT06671392, source copy `cardio:ctgov-nct06671392-2026-03-19`, retrieved 2026-10-26)
- Started: 2025-02-24 (actual) (ClinicalTrials.gov record NCT06671392, source copy `cardio:ctgov-nct06671392-2026-03-19`, retrieved 2026-10-26)
- Primary completion: 2026-02-05 (actual) (ClinicalTrials.gov record NCT06671392, source copy `cardio:ctgov-nct06671392-2026-03-19`, retrieved 2026-10-26)
- Completion: 2026-02-05 (actual) (ClinicalTrials.gov record NCT06671392, source copy `cardio:ctgov-nct06671392-2026-03-19`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06671392, source copy `cardio:ctgov-nct06671392-2026-03-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06671392-2026-03-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase III Study to Efficacy and Safety of DWC202405/DWC202313 and DWC202314 in Patients With Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): DWC202405
- Intervention (Drug): DWC202405, DWC202314
- Intervention (Drug): DWC202405, DWC202314P
- Intervention (Drug): DWC202313, DWC202314
- Intervention (Drug): DWC202313, DWC202314P
- Lead sponsor: Daewoong Pharmaceutical Co. LTD.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

## Provenance

Content hash: f50009ee05cbe1a1dbe6936561845f55526890757996c9e781cd848e841fe6b7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
